Demetrius Maraganore

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc High-resolution whole-genome association study of Parkinson disease
    Demetrius M Maraganore
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Am J Hum Genet 77:685-93. 2005
  2. pmc Beyond Parkinson disease: amyotrophic lateral sclerosis and the axon guidance pathway
    Timothy G Lesnick
    Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 3:e1449. 2008
  3. pmc In vivo silencing of alpha-synuclein using naked siRNA
    Jada Lewis
    Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Mol Neurodegener 3:19. 2008
  4. ncbi A limited role for DJ1 in Parkinson disease susceptibility
    D M Maraganore
    Department of Neurology, Mayo Clinic Rochester, MN 55905, USA
    Neurology 63:550-3. 2004
  5. ncbi UCHL1 is a Parkinson's disease susceptibility gene
    Demetrius M Maraganore
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Ann Neurol 55:512-21. 2004
  6. ncbi Complex interactions in Parkinson's disease: a two-phased approach
    Demetrius M Maraganore
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Mov Disord 18:631-6. 2003
  7. ncbi Autopsy patterns for Parkinson's disease and related disorders in Olmsted County, Minnesota
    D M Maraganore
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Neurology 53:1342-4. 1999
  8. ncbi Case-control study of the alpha-synuclein interacting protein gene and Parkinson's disease
    Demetrius M Maraganore
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mov Disord 18:1233-9. 2003
  9. ncbi Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease
    Demetrius M Maraganore
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    JAMA 296:661-70. 2006
  10. ncbi Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease
    D M Maraganore
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Neurology 53:1858-60. 1999

Research Grants

  1. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2000
  2. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2008
  3. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2007
  4. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2006
  5. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2004
  6. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2003
  7. Supplement-ES10751 (Molecular Epidemiology of PD)
    Demetrius Maraganore; Fiscal Year: 2003
  8. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2002
  9. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2001
  10. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2009

Detail Information

Publications58

  1. pmc High-resolution whole-genome association study of Parkinson disease
    Demetrius M Maraganore
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Am J Hum Genet 77:685-93. 2005
    ..07 x 10(-6); P=2.96 x 10(-5)) tagged the PARK10 late-onset PD susceptibility locus. Independent replication across populations will clarify the role of the genomic loci tagged by these SNPs in conferring PD susceptibility...
  2. pmc Beyond Parkinson disease: amyotrophic lateral sclerosis and the axon guidance pathway
    Timothy G Lesnick
    Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 3:e1449. 2008
    ..We also demonstrated that several axon guidance pathway genes represented by SNPs within our final models were differentially expressed in PD...
  3. pmc In vivo silencing of alpha-synuclein using naked siRNA
    Jada Lewis
    Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Mol Neurodegener 3:19. 2008
    ..Genetic variability in SNCA contributes to risk of idiopathic Parkinson's disease (PD), possibly as a result of overexpression. SNCA downregulation is therefore a valid therapeutic target for PD...
  4. ncbi A limited role for DJ1 in Parkinson disease susceptibility
    D M Maraganore
    Department of Neurology, Mayo Clinic Rochester, MN 55905, USA
    Neurology 63:550-3. 2004
    ..None of the four haplotype tagging single-nucleotide polymorphisms (SNPs) was associated with PD overall, but SNP1 (position 4,345 bp) and SNP3 (position 16,491 bp) were associated with PD in women (p = 0.03 and p = 0.002)...
  5. ncbi UCHL1 is a Parkinson's disease susceptibility gene
    Demetrius M Maraganore
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Ann Neurol 55:512-21. 2004
    ..These findings confirm that UCHL1 is a susceptibility gene for PD and a potential target for disease-modifying therapies...
  6. ncbi Complex interactions in Parkinson's disease: a two-phased approach
    Demetrius M Maraganore
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Mov Disord 18:631-6. 2003
    ..42; P = 0.003). Our findings are consistent with the hypothesis that PD is a multigenic disorder of the UPS...
  7. ncbi Autopsy patterns for Parkinson's disease and related disorders in Olmsted County, Minnesota
    D M Maraganore
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Neurology 53:1342-4. 1999
    ..The overall autopsy rate was low (23%). Diagnostic certainty (for PD), diagnostic type (PD versus other parkinsonism), sex, age at death, and location at death were important selection factors for autopsy...
  8. ncbi Case-control study of the alpha-synuclein interacting protein gene and Parkinson's disease
    Demetrius M Maraganore
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mov Disord 18:1233-9. 2003
    ..0001). Recursive partitioning showed no interactions between variants of the SNCAIP gene and variants of the alpha-synuclein gene (SNCA) or the parkin (PARK2) gene...
  9. ncbi Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease
    Demetrius M Maraganore
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    JAMA 296:661-70. 2006
    ..Alpha-synuclein (SNCA) has been one of the most promising susceptibility genes, but large-scale studies have been lacking...
  10. ncbi Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease
    D M Maraganore
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Neurology 53:1858-60. 1999
    ..However, S18Y polymorphism carriers had significantly lower risk of PD (odds ratio = 0.53; p = 0.03), and the risk reduction was greater for younger onset cases...
  11. ncbi Case-Control study of the extended tau gene haplotype in Parkinson's disease
    D M Maraganore
    Department of Neurology Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Neurol 50:658-61. 2001
    ....
  12. ncbi Case-control study of estrogen receptor gene polymorphisms in Parkinson's disease
    Demetrius M Maraganore
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Mov Disord 17:509-12. 2002
    ..While exogenous and endogenous estrogen may modify the risk of PD in women, the two estrogen receptor gene polymorphisms considered here do not seem to contribute to PD susceptibility...
  13. ncbi Complex relationship between Parkin mutations and Parkinson disease
    Andrew West
    Familial Movement Disorders, Laboratories of Neurogenetics, Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, USA
    Am J Med Genet 114:584-91. 2002
    ....
  14. ncbi Interaction of alpha-synuclein and tau genotypes in Parkinson's disease
    Catherine E Mamah
    Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Ann Neurol 57:439-43. 2005
    ..These findings are consistent with in vitro experiments that revealed tau-mediated fibrillization of alpha-synuclein protein at low concentrations (dose threshold effect)...
  15. ncbi Complex segregation analysis of Parkinson's disease: The Mayo Clinic Family Study
    Shannon K McDonnell
    Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Ann Neurol 59:788-95. 2006
    ..To conduct complex segregation analyses of Parkinson's disease (PD)...
  16. ncbi Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort study
    Alexis Elbaz
    Departments of Health Sciences Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Mov Disord 20:719-25. 2005
    ..Among PD patients, there was no relation between the risk of cancer and the cumulative dose of levodopa received or the use of other PD medications...
  17. ncbi Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease
    John L Goudreau
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Mov Disord 17:1305-11. 2002
    ..These significant differences at the two-tailed alpha level of 0.05 and restricted to subgroup analyses may have a biological basis or may be chance findings...
  18. ncbi UCHL1 is associated with Parkinson's disease: a case-unaffected sibling and case-unrelated control study
    Maurizio Facheris
    Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Neurosci Lett 381:131-4. 2005
    ..Analyses confirmed a significant inverse association of the UCHL1 S18Y polymorphism with PD overall (OR=0.18, 95% CI=0.05-0.64, p=0.002, recessive model) and in several strata...
  19. ncbi Risk tables for parkinsonism and Parkinson's disease
    Alexis Elbaz
    Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Epidemiol 55:25-31. 2002
    ..Lifetime risk estimates are useful in clinical practice, epidemiologic research, and public health...
  20. pmc Beta-synuclein gene variants and Parkinson's disease: a preliminary case-control study
    Laura Brighina
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurosci Lett 420:229-34. 2007
    ..The results of this preliminary study suggest that the SNCB locus, though not a susceptibility gene for PD, might modify the age at onset of PD...
  21. ncbi Medical services utilization and prognosis in Parkinson disease: a population-based study
    Sotirios A Parashos
    Department of Neurology, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:918-25. 2002
    ..To investigate prognostic outcomes and utilization of medical services by patients with Parkinson disease (PD) and to identify predictors of such use...
  22. ncbi Number of children and risk of Parkinson's disease
    Roberta Frigerio
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mov Disord 22:632-9. 2007
    ..The independent replication in two distinct populations and using different epidemiologic study designs may suggest a link between the number of children and PD restricted to men...
  23. ncbi Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications
    Matt Farrer
    Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
    Ann Neurol 55:174-9. 2004
    ..The profound implications of alpha-synuclein overexpression for idiopathic synucleinopathies are discussed...
  24. ncbi The Mayo Clinic cohort study of personality and aging: design and sampling, reliability and validity of instruments, and baseline description
    Walter A Rocca
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neuroepidemiology 26:119-29. 2006
    ..68, p < 0.0001). This newly established historical cohort study provides opportunities to test hypotheses regarding the link between personality and aging, aging-related diseases, and overall mortality...
  25. ncbi Direct medical costs associated with Parkinson's disease: a population-based study
    Cynthia L Leibson
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Mov Disord 21:1864-71. 2006
    ..99, for those with tremor). These population-based estimates of PD-associated direct medical costs from onset forward can uniquely inform policy decisions and cost-effectiveness research...
  26. ncbi Increased risk of essential tremor in first-degree relatives of patients with Parkinson's disease
    Walter A Rocca
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Mov Disord 22:1607-14. 2007
    ..These findings suggest that PD and ET may share familial susceptibility factors...
  27. ncbi Risk of cognitive impairment or dementia in relatives of patients with Parkinson disease
    Walter A Rocca
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 64:1458-64. 2007
    ..The evidence for increased risk of dementia in relatives of patients with Parkinson disease (PD) remains conflicting...
  28. pmc The long-term effects of oophorectomy on cognitive and motor aging are age dependent
    Walter A Rocca
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Neurodegener Dis 5:257-60. 2008
    ..The evidence for a neuroprotective effect of estrogen in women remains controversial...
  29. pmc Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging
    Walter A Rocca
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Womens Health (Lond Engl) 5:39-48. 2009
    ..Results from other studies are cited as evidence for or against each possible mechanism. These putative causal mechanisms are probably intertwined, and their clarification is a research priority...
  30. pmc Anxious personality predicts an increased risk of Parkinson's disease
    James H Bower
    Department of Neurology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mov Disord 25:2105-13. 2010
    ..Our long-term historical cohort study suggests that an anxious personality trait may predict an increased risk of PD developing many years later...
  31. ncbi Comorbid conditions associated with Parkinson's disease: a population-based study
    Cynthia L Leibson
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mov Disord 21:446-55. 2006
    ..The excess morbidity and mortality observed for persons with PD are consistent with recognized PD sequelae...
  32. doi Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy
    Walter A Rocca
    Division of Epidemiology, Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Menopause 15:1050-9. 2008
    ..We studied the long-term risk of depressive and anxiety symptoms in women who underwent bilateral oophorectomy before menopause...
  33. ncbi Clinical correlates of the pathology underlying parkinsonism: a population perspective
    James H Bower
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Mov Disord 17:910-6. 2002
    ..Despite this selection bias, the retrospective data collection, and the small sample size, we made several observations that illustrate the difficulty in achieving an accurate antemortem diagnosis of parkinsonism...
  34. ncbi Nonfatal cancer preceding Parkinson's disease: a case-control study
    Alexis Elbaz
    Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Epidemiology 13:157-64. 2002
    ..We conducted a population-based case-control study to investigate the association of Parkinson's disease (PD) with preceding nonfatal cancer...
  35. ncbi Familial aggregation of Parkinson's disease: The Mayo Clinic family study
    Walter A Rocca
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Ann Neurol 56:495-502. 2004
    ..62; 95% confidence interval, 1.66-4.15), whereas relatives of probands with later onset had no increased risk. The relative risk decreased when the incidence of all types of parkinsonism was considered...
  36. ncbi Fracture risk after the diagnosis of Parkinson's disease: Influence of concomitant dementia
    L Joseph Melton
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Mov Disord 21:1361-7. 2006
    ..1). The increased fracture risk in patients with PD is not entirely explained by concomitant dementia, and additional study is needed to determine the relative contributions to fracture risk of falls versus bone loss in these patients...
  37. ncbi The Mayo Clinic family study of Parkinson's disease: study design, instruments, and sample characteristics
    Walter A Rocca
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minn, USA
    Neuroepidemiology 24:151-67. 2005
    ..Finally, we studied a group of 625 spouses of either cases or controls. Relatives with PD or other neurodegenerative diseases were ascertained using the family study method...
  38. ncbi Chemical exposures and Parkinson's disease: a population-based case-control study
    Roberta Frigerio
    Division of Epidemiology, Department of Health Sciences Research, Mayo College of Medicine, Rochester, Minnesota 55905, USA
    Mov Disord 21:1688-92. 2006
    ..This population-based study suggests a link between pesticides use and PD that is restricted to men. Pesticides may interact with other genetic or nongenetic factors that are different in men and women...
  39. ncbi Reliability of self-reported ancestry among siblings: implications for genetic association studies
    Melinda S Burnett
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Am J Epidemiol 163:486-92. 2006
    ..Self-reported ancestry may not be a reliable method to reduce the possible impact of population stratification in genetic association studies of outbred populations, such as in the United States...
  40. pmc Genomic investigation of alpha-synuclein multiplication and parkinsonism
    Owen A Ross
    Division of Neurogenetics, Department of Neuroscience, College of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA
    Ann Neurol 63:743-50. 2008
    ..Herein we characterize five families with parkinsonism that have been identified to harbor multiplication of the chromosomal 4q21 locus containing the alpha-synuclein gene (SNCA)...
  41. pmc Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease
    Roberta Frigerio
    Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55902, USA
    Arch Neurol 66:1114-9. 2009
    ..To explore whether associations of potential risk factors for incidental Lewy body disease (iLBD) are similar to those for Parkinson disease (PD)...
  42. ncbi Bell's palsy preceding Parkinson's disease: a case-control study
    Rodolfo Savica
    Division of Epidemiology, Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mov Disord 24:1530-3. 2009
    ..5 years (range, 2-54 years). The findings were similar using a standardized incidence ratio (SIR) approach, but were not statistically significant. This initial association between BP and PD awaits replication...
  43. ncbi Survival study of Parkinson disease in Olmsted County, Minnesota
    Alexis Elbaz
    Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Arch Neurol 60:91-6. 2003
    ..To compare survival in incident cases of Parkinson disease (PD) with survival in subjects free of PD from the general population...
  44. doi Coffee, caffeine-related genes, and Parkinson's disease: a case-control study
    Maurizio F Facheris
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mov Disord 23:2033-40. 2008
    ..Our study neither supports the hypothesis that coffee protects against PD nor provides evidence for a pharmacogenetic effect...
  45. pmc A genomic pathway approach to a complex disease: axon guidance and Parkinson disease
    Timothy G Lesnick
    Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America
    PLoS Genet 3:e98. 2007
    ..This genomic pathway approach may also offer insights into other complex diseases such as Alzheimer disease, diabetes mellitus, nicotine and alcohol dependence, and several cancers...
  46. ncbi Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson disease
    Gennarina Arabia
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Arch Gen Psychiatry 64:1385-92. 2007
    ..Relatives of patients with Parkinson disease (PD) have an increased risk of PD and other neurologic disorders; however, their risk of psychiatric disorders remains uncertain...
  47. pmc Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations
    Jennifer Kachergus
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
    Am J Hum Genet 76:672-80. 2005
    ..Our work highlights the fact that a proportion of clinically typical, late-onset PD cases have a genetic basis...
  48. ncbi Increased risk of head tremor in women with essential tremor: longitudinal data from the Rochester Epidemiology Project
    David E Hardesty
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Mov Disord 19:529-33. 2004
    ..The reason for the association between gender and head tremor, which has now been demonstrated in several studies, is not known, but it could reflect gender differences in the distribution of disease pathology within the brain...
  49. ncbi Parkinson's disease in Africa: A systematic review of epidemiologic and genetic studies
    Njideka U Okubadejo
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    Mov Disord 21:2150-6. 2006
    ..There are no case-control or cohort studies of PD reported from Africa. This review provides a summary of PD research in Africa over the past 60 years and highlights the information gaps and potential areas for future research...
  50. pmc Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure
    Axel Lipp
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Arch Neurol 66:742-50. 2009
    ....
  51. ncbi Parkin variants in North American Parkinson's disease: cases and controls
    Sarah J Lincoln
    Department of Neuroscience, Mayo Clinic Jacksonville, Florida 32224, USA
    Mov Disord 18:1306-11. 2003
    ..Furthermore, only stratified subanalyses detected any genetic association between the V380L common coding polymorphism and PD. We discuss the implication of parkin mutations for Parkinson's disease from this population perspective...
  52. ncbi Blood is thicker than water: the strengths of family-based case-control studies
    Demetrius M Maraganore
    Neurology 64:408-9. 2005
  53. ncbi Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease
    Qing Rong Liu
    Molecular Neurobiology Branch, National Institute on Drug Abuse Intramural Research Program NIDA IRP, NIH, Department of Health and Human Services DHHS, Baltimore, Maryland, USA
    Am J Med Genet B Neuropsychiatr Genet 134:93-103. 2005
    ..Association studies of BDNF variants reveal no associations with Parkinson's disease. Comparisons between substance abusers and controls reveal modest associations. These findings increase interest in this diverse human gene...
  54. ncbi Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease
    George D Mellick
    Department of Neurology, School of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
    Neurosci Lett 375:112-6. 2005
    ..79, 95% CI 0.70-0.89, p=0.0001). Further study must now proceed to examine in detail this interesting and biologically plausible genetic association...
  55. ncbi Prevalence of Parkinson's disease and related disorders in the elderly population of greater Beijing, China
    Zhen Xin Zhang
    Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
    Mov Disord 18:764-72. 2003
    ..The prevalence figures obtained in this study are similar to some of the highest prevalence figures reported in the West...
  56. ncbi A road map for efficient and reliable human genome epidemiology
    John P A Ioannidis
    Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, and Biomedical Research Institute, Foundation for Research and Technology Hellas, Ioannina 45110, Greece
    Nat Genet 38:3-5. 2006
    ..Systematic reviews will be expanded to include more meta-analyses of individual-level data and prospective meta-analyses. Field synopses will offer regularly updated overviews...
  57. ncbi Essential tremor associated with focal nonnigral Lewy bodies: a clinicopathologic study
    Elan D Louis
    Gertrude H Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Arch Neurol 62:1004-7. 2005
    ..Essential tremor is one of the most common neurological diseases. Its links with Parkinson disease (PD) are often debated. There have been few published postmortem studies...
  58. ncbi Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease
    J Eric Ahlskog
    JAMA 288:311; author reply 312-3. 2002

Research Grants10

  1. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2000
    ..We specifically address the RFA's objectives of evaluating endogenous (including biomarkers) and exogenous (including dietary and lifestyle) susceptibility factors for PD using molecular epidemiology tools. ..
  2. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2008
    ..They will also accelerate the development of new treatments, reduce research and development costs, and identify subgroups of patients most likely to benefit. ..
  3. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2007
    ..They will also accelerate the development of new treatments, reduce research and development costs, and identify subgroups of patients most likely to benefit. ..
  4. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2006
    ..They will also accelerate the development of new treatments, reduce research and development costs, and identify subgroups of patients most likely to benefit. ..
  5. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2004
    ..We specifically address the RFA's objectives of evaluating endogenous (including biomarkers) and exogenous (including dietary and lifestyle) susceptibility factors for PD using molecular epidemiology tools. ..
  6. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2003
    ..We specifically address the RFA's objectives of evaluating endogenous (including biomarkers) and exogenous (including dietary and lifestyle) susceptibility factors for PD using molecular epidemiology tools. ..
  7. Supplement-ES10751 (Molecular Epidemiology of PD)
    Demetrius Maraganore; Fiscal Year: 2003
    ..The proposed aims represent a significant amplification and expansion of the investigators' ongoing work. The proposed studies will provide an invaluable genetic framework for anticipated toxicogenomic studies of PD. ..
  8. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2002
    ..We specifically address the RFA's objectives of evaluating endogenous (including biomarkers) and exogenous (including dietary and lifestyle) susceptibility factors for PD using molecular epidemiology tools. ..
  9. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2001
    ..We specifically address the RFA's objectives of evaluating endogenous (including biomarkers) and exogenous (including dietary and lifestyle) susceptibility factors for PD using molecular epidemiology tools. ..
  10. MOLECULAR EPIDEMIOLOGY OF PARKINSON'S DISEASE
    Demetrius Maraganore; Fiscal Year: 2009
    ..They will also accelerate the development of new treatments, reduce research and development costs, and identify subgroups of patients most likely to benefit. ..